NDT Advance Access originally published online on June 28, 2005
Nephrology Dialysis Transplantation 2005 20(10):2146-2152; doi:10.1093/ndt/gfh919
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review
1 Western New England Renal and Transplant Associates, Springfield, MA, 2 Dallas Nephrology Associates, Dallas, TX, 3 Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, 4 Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ and 5 Diablo Nephrology Medical Group, Walnut Creek, CA, USA
Correspondence and offprint requests to: Michael Germain, MD, Western New England Renal and Transplant Associates, 300 Birne Avenue, Suite 300, Springfield, MA 01107, USA. Email: Michael.Germain{at}bhs.org
Background. The effectiveness of extended dosing of epoetin alfa beyond once-weekly (QW) has not been well explored in patients being treated for anaemia of chronic kidney disease (CKD). The current study was undertaken to assess the effectiveness of extended dosing in maintaining haemoglobin (Hb) levels in this population.
Methods. A retrospective chart review was conducted to assess the efficacy of extended epoetin alfa dosing in patients being treated for CKD-related anaemia. Eligible patients were to have received epoetin alfa once every 2 weeks (Q2W), 3 weeks (Q3W), 4 weeks (Q4W), or >Q4W administered subcutaneously for at least 3 months to maintain Hb 
11.0 g/dl. Patients were 18 years with serum creatinine 1.5 to 6.0 mg/dl for females and 2.0 to 6.0 mg/dl for males, and were not receiving renal replacement therapy. Epoetin alfa dose and dosing frequency were adjusted during treatment at the clinician's discretion. For analysis, patients were stratified into dosing groups based on their most dominant dosing regimen.
Results. 243 patients (mean age, 71.5 years; 79% white, 54% female) who received extended epoetin alfa dosing for a mean of 10.3 months were eligible for analysis. Mean baseline estimated glomerular filtration rate and mean serum creatinine were 21.2 ml/min/1.73 m2 and 3.1 mg/dl, respectively. Primary causes of CKD included hypertension (36%) and diabetes (28%). Most patients (82%) receiving an extended epoetin alfa regimen maintained Hb 11.0 g/dl. The most common dosing regimen was Q2W (51%). Mean Hb for each dosing group was maintained between 11.6 g/dl and 12.4 g/dl during the study, and glomerular filtration rate remained stable. Epoetin alfa was well tolerated across all groups.
Conclusions. Data from private community nephrology practices showed that extended epoetin alfa dosing effectively maintained Hb 11.0 g/dl in 82% of these selected patients being treated for anaemia of CKD.
Keywords: anaemia correction; chronic renal disease; epoetin; epoetin dosage; haemoglobin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Spinowitz, M. Germain, R. Benz, M. Wolfson, T. McGowan, K. L. Tang, M. Kamin, and for the Epoetin Alfa Extended Dosing Study Group A Randomized Study of Extended Dosing Regimens for Initiation of Epoetin Alfa Treatment for Anemia of Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1015 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. McGowan, N. M. Vaccaro, J. S. Beaver, J. Massarella, and M. Wolfson Pharmacokinetic and Pharmacodynamic Profiles of Extended Dosing of Epoetin Alfa in Anemic Patients Who Have Chronic Kidney Disease and Are Not on Dialysis Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1006 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Wish and D. W. Coyne Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations of Existing Therapies Mayo Clin. Proc., November 1, 2007; 82(11): 1371 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Singh, L. Szczech, K. L. Tang, H. Barnhart, S. Sapp, M. Wolfson, and D. Reddan Anaemia of CKD--the CHOIR study revisited Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1806 - 1810. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gilmartin Pharmacist's role in managing anemia in patients with chronic kidney disease: Potential clinical and economic benefits Am. J. Health Syst. Pharm., July 1, 2007; 64(13_Supplement_8): S15 - S22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Benz, R. Schmidt, K. Kelly, and M. Wolfson Epoetin Alfa Once Every 2 Weeks Is Effective for Initiation of Treatment of Anemia of Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 215 - 221. [Abstract] [Full Text] [PDF]
|
|